BTWM
VRTX icon

Baker Tilly Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Baker Tilly Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
3,315
+127
+4% +$56.3K 0.35% 55
2026
Q1 		$1.42M Buy
3,188
+79
+3% +$36.8K 0.35% 52
2025
Q4 		$1.41M Buy
3,109
+28
+0.9% +$12.1K 0.35% 52
2025
Q3 		$1.21M Buy
3,081
+173
+6% +$72.3K 0.27% 62
2025
Q2 		$1.29M Sell
2,908
-80
-3% -$36.9K 0.46% 36
2025
Q1 		$1.45M Buy
2,988
+1,092
+58% +$509K 0.57% 30
2024
Q4 		$764K Sell
1,896
-393
-17% -$182K 0.3% 81
2024
Q3 		$1.06M Buy
2,289
+401
+21% +$193K 0.47% 49
2024
Q2 		$885K Sell
1,888
-880
-32% -$382K 0.36% 63
2024
Q1 		$1.16M Buy
2,768
+42
+2% +$17.8K 0.21% 112
2023
Q4 		$1.11M Sell
2,726
-569
-17% -$210K 0.18% 125
2023
Q3 		$1.15M Sell
3,295
-6,439
-66% -$2.25M 0.19% 115
2023
Q2 		$3.43M Buy
9,734
+249
+3% +$83.9K 0.36% 65
2023
Q1 		$2.99M Sell
9,485
-274
-3% -$82.2K 0.34% 65
2022
Q4 		$2.82M Buy
9,759
+880
+10% +$268K 0.35% 71
2022
Q3 		$2.57M Buy
8,879
+498
+6% +$143K 0.35% 65
2022
Q2 		$2.36M Sell
8,381
-901
-10% -$241K 0.31% 72
2022
Q1 		$2.42M Buy
9,282
+1,510
+19% +$358K 0.27% 79
2021
Q4 		$1.71M Buy
7,772
+1,081
+16% +$210K 0.18% 115
2021
Q3 		$1.21M Buy
+6,691
New +$1.31M 0.16% 131

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Baker Tilly Wealth Management's VRTX Position: Q2 2026 in Review

Baker Tilly Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, buying an estimated $56.3K and bringing the position to 3,315 shares worth $1.65M. The position accounts for 0.35% of the portfolio, ranked #55.

Baker Tilly Wealth Management first reported a position in VRTX in Q3 2021 and has held it in 20 quarters since. The position peaked at $3.43M in Q2 2023. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Baker Tilly Wealth Management held 3,315 shares of Vertex Pharmaceuticals worth $1.65M as of Q2 2026.
  • Baker Tilly Wealth Management bought 127 Vertex Pharmaceuticals shares in Q2 2026, an estimated $56.3K.
  • Vertex Pharmaceuticals made up 0.35% of Baker Tilly Wealth Management's portfolio in Q2 2026, its #55 holding.
  • Baker Tilly Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Baker Tilly Wealth Management's Vertex Pharmaceuticals position peaked at $3.43M in Q2 2023.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Baker Tilly Wealth Management's 13F filing for Q2 2026, filed 17 Jul 2026.